Women Square

Tag: ENTOD Pharmaceuticals

  • National Hearing Week 2026 Reaches Over 5 Crore People Across India, Strengthening Awareness on Early Hearing Screening in Children

    National Hearing Week 2026 Reaches Over 5 Crore People Across India, Strengthening Awareness on Early Hearing Screening in Children

    National, India 29 March 2026: Matanand Welfare Foundation and ENTOD Pharmaceuticals’ #HarBacchaSunega campaign, organized during the National Hearing Week 2026 (March 3-8), swept across India, reaching 5 crore people to spotlight childhood hearing loss and urgent early screening. Organized under the theme, “Hear Their World: Early Detection, Early Action,” it aimed to educate parents, teachers, and healthcare professionals on recognizing early signs of hearing loss and ensuring timely diagnosis and treatment.

    The campaign witnessed strong participation from the medical community, with over 2,500 ENT specialists across India supporting awareness and screening initiatives. More than 2,000 hearing awareness and screening camps were conducted at clinics, hospitals, and community centres nationwide, benefiting nearly 2,00,000 patients and their families. In addition, free ear health screening and awareness sessions were organized in over 200 schools, reaching more than 20,000 students and educating teachers and parents on the importance of early hearing checks.

    Dr Milind Navlakhe, Professor and HOD – ENT DEPARTMENT, Lokmanya Tilak Municipal General Hospital and Medical College, Mumbai – “Early hearing screening transforms lives, undiagnosed loss steals vital speech and language development from children, but simple tests at birth or school entry can open their world and enhance cognitive growth. Children treated by 3-6 months achieve far better vocabulary and school readiness than those diagnosed later.”

    “Partnering on #HarBacchaSunega perfectly aligns with ENTOD’s mission to advance ear health and empower communities. Reaching 5 crore voices demonstrates how targeted awareness can spark real, lasting change, ensuring no child misses out on hearing, learning, and thriving. We’re proud to fuel this movement alongside Matanand Welfare Foundation,” states Nikkhil K. Masurkar, CEO, ENTOD Pharmaceuticals.

    Community engagement played a key role in amplifying awareness, with over 50 rallies, walkathons, and street awareness activities organized in collaboration with leading ENT hospitals, government hospitals, medical institutions, and medical colleges across the country. These activities helped spread important messages about early detection of hearing problems and preventive ear care among local communities.

    The #HarBacchaSunega campaign surged national visibility via dynamic digital-media outreach: 200+ ENT doctors joined www.nationalhearingweek.org, sharing 150+ regional-language videos and 500+ social media stories. Times Now TV hosted a key discussion with ENTOD CEO Nikkhil K. Masurkar and Dr. Renuka Bradoo on early childhood hearing screening, while Radio City 91.1 FM aired Dr. Hetal Marfatia Patel’s vodcast plus awareness messages across 10 cities.

    Through nationwide medical outreach, community participation, media engagement, and digital awareness initiatives, National Hearing Week 2026 reinforced the importance of early hearing screening and preventive ear care, working toward the larger goal of ensuring that every child in India has the opportunity to hear, learn, and thrive.

    About ENTOD Pharmaceuticals

    ENTOD Pharmaceuticals is a global research-driven pharma company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2000+ strong global team, and presence in 67 countries, ENTOD’s products meet the highest international GMP and European-certified quality standards.

  • ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

    ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

    Highlights:

    • Global discussions spotlight early screening and ROP prevention as critical public health priorities for India
    • International collaboration highlights scalable solutions to reduce avoidable childhood blindness
    • Innovation-led partnerships key to safeguarding every child’s right to sight

    New Delhi, 12th February, 2026: ENTOD Pharmaceuticals, a global ophthalmology-focused pharmaceutical company, reaffirmed its commitment to preventing avoidable childhood blindness in India by participating in global deliberations marking the International Day for a World Without Childhood Blindness. The discussions, led by the Eye Foundation of America (EFA) in collaboration with Rotary International, Lions International, the United Nations, the Commonwealth Secretariat, and civil society institutions, focused on strengthening prevention-led approaches to childhood eye health, including early screening and timely intervention for conditions such as retinopathy of prematurity (ROP).

    ENTOD Pharmaceuticals was represented by its Chairman, Mr. Kishore Gurudas Masurkar, and CEO, Mr. Nikkhil K Masurkar, at the commemoration held at the UK House of Lords, one of the world’s most influential legislative chambers. The engagement reflected ENTOD’s focus on aligning global best practices with India’s evolving paediatric eye-care needs.

    The initiative was led by the Eye Foundation of America (EFA) in collaboration with Rotary International, Lions International, the United Nations, the Commonwealth Secretariat, and civil society institutions, with a shared objective of strengthening prevention-led approaches to childhood blindness. Discussions placed strong emphasis on ROP prevention, which has emerged as a leading cause of avoidable blindness among premature infants in India.

    The high-level forum brought together global health leaders, parliamentarians, policymakers, philanthropists, and vision advocates, including Lord Rami Ranger, Dr. V. K. Raju, Siddharth Chatterjee (United Nations Resident Coordinator), Dr. Varaprasad Reddy, and Dr. Mukesh Batra, underscoring the importance of coordinated, system-level collaboration.

    A key global commitment highlighted was a USD 1 million pledge by the Eye Foundation of America to support the launch of India’s National Retinopathy of Prematurity (ROP) Program, in partnership with Rotary and Lions, aimed at strengthening early screening, timely treatment, and access to specialised care for at-risk infants.

    Aligned with the UN Sustainable Development Goal 3 (Good Health and Well-Being), the discussions reinforced the importance of innovation-led collaboration in reducing preventable childhood blindness.

    For ENTOD Pharmaceuticals, childhood vision care has long been a core focus, driving innovation in paediatric ophthalmology, myopia control, and vision-preserving therapies, and supporting India’s efforts to ensure every child’s right to sight.

    About ENTOD Pharmaceuticals

    ENTOD Pharmaceuticals is a global research-driven pharma company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2000+ strong global team, and presence in 67 countries, ENTOD’s products meet the highest international GMP and European-certified quality standards.

  • ENTOD Launches OCUBIOME™: A New Era in Eye Care

    ENTOD Launches OCUBIOME™: A New Era in Eye Care

    New Delhi, 10 October 2025: ENTOD Pharmaceuticals, a global leader in eye health innovation, has announced the launch of OCUBIOME™, India’s first ocular probiotic blend developed to support healthy eyes. The proprietary formulation was created at the company’s advanced R&D centre in Navi Mumbai.

    Addressing Modern Eye Health Challenges

    In today’s fast-paced, screen-heavy lifestyle, issues like dry eye syndrome, ocular discomfort, and post-surgical recovery complications are increasingly common. Millions experience symptoms such as burning eyes, blurred vision, and eye fatigue. While lubricants provide temporary relief, long-term management remains a challenge.

    OCUBIOME™ offers a holistic approach by restoring the balance of both ocular and gut microbiota, complementing traditional therapies and providing sustained benefits beyond immediate relief.

    A Convenient Daily Routine

    Delivered in mouth-melting, no-added-sugar sachets, OCUBIOME™ is designed for once-daily use. It supports ocular comfort, digital eye strain recovery, and promotes long-term eye health in a simple and convenient way.

    Expert Insights

    “Eye health today cannot be addressed in isolation – it is impacted by lifestyle, environment, and recovery needs after surgery. With OCUBIOME™, ENTOD is introducing a category-first innovation that brings freshness and convenience to how we manage ocular wellness,”
    — Mr. Nikkhil K Masurkar, CEO, ENTOD Pharmaceuticals.

    “Ocular health must be considered within the broader systemic context. Evidence shows that the gut microbiome plays a direct role in ocular inflammation and disease progression. ENTOD’s probiotic innovation provides clinicians with a scientifically supported option to improve outcomes in conditions such as dry eye and post-surgical recovery,”
    — Dr. Hitesh Chheda, Medical Director, Asian Eye Institute & Laser Centre.

    A New Era in Preventive Eye Care

    The launch of OCUBIOME™ represents a turning point in proactive ocular wellness, aligning with growing scientific interest in the gut–eye axis. By bridging gut and eye health, ENTOD aims to empower patients and clinicians with a preventive, science-backed solution that goes beyond symptom relief.

    Availability: OCUBIOME™ will be available by prescription from November 2025.

    About ENTOD Pharmaceuticals

    ENTOD Pharmaceuticals is a global research-driven pharmaceutical company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2000+ strong global team, and presence in 67 countries, ENTOD adheres to the highest GMP and European-certified quality standards, continuing to pioneer innovation in eye health.